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Abstract
In this work the effects of citric acid and of two common fillers, lactose (soluble) and tricalcium phosphate (insoluble) are
examined on the release profiles from pellets, using ibuprofen as a model drug with pH-dependent solubility. Also studied is the
dependence of these profiles on the specific surface area, bulk density, apparent density, porosity and porosity parameters (pore
size distribution, total pore surface area, mean pore diameter and pore shape), as determined by mercury intrusion porosimetry.
Pellets with high porosity and total pore surface area but small median pore diameter (tricalcium phosphate pellets—IPM) are
found to produce similar dissolution results to those of low porosity and low total pore surface area, but having a high median pore
diameter (lactose pellets—ILM), irrespective of the solubility of excipients. Addition of citric acid causes a delay in the initial
dissolution for both formulations. During dissolution, however, citric acid reduces the median pore diameter of lactose-based
pellets. In contrast, in tricalcium phosphate/citric acid pellets (CIPM), this parameter increases considerably during dissolution,
when compared to the IPM formulation. These findings may justify the contrasting dissolution behaviors of CIPM and CILM
(lactose/citric acid) pellets, after their common behavior in the initial stages, and show that porosity and its related parameters,
along with physical properties of excipients such as solubility, density and specific surface area, are helpful to predict pellet
behavior in drug release profiles.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Extrusion-spheronization technology (Conine and
Hadley, 1970; Reynolds, 1970) has been adopted by
the pharmaceutical industry for production of pellets,
which can be either filled into capsules or compacted
into tablet form . Factors that mostly influence pel-
let production have been studied and found to be re-
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lated to formulation (Tomer et al., 2001; Sousa et al.,
2002a,b), processing conditions (Sousa et al., 1996;
Chopra et al., 2001; Alvarez et al., 2002) and equip-
ment used (Berggren and Alderborn, 2001; Pinto et al.,
2001).
Formulation parameters, irrespective of the solid
dosage form, influence both the process and the qual-
ity of the final product. The presence of soluble or
insoluble fillers (Khan and Zhu, 1998; Sousa et al.,
2002a) and of organic acids as pH adjusters (Nykänen
et al., 1999; Krogars et al., 2000) have already been
identified as factors which can modulate drug release.
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In particular, the morphology of pellets and total
structure can change with any variation in formulation
or in materials properties, affecting quality parame-
ters such as porosity and surface roughness (Chopra
et al., 2001). These properties are considered to have
a great influence on coating, flow and packing during
capsule filling or tabletting (Rodriguez et al., 2001;
Johansson and Alderborn, 2001). Porosity and pore
structure can also provide relevant information for
predicting the disintegration, dissolution, adsorption
and diffusion behavior of drugs (Dees and Polderman,
1981). Recent studies (Mehta et al., 2000) have shown
that porosity parameters, such as pore size distribu-
tion, total pore surface area, mean pore diameter and
pore shape of pellets formulated with an insoluble
drug, correlate with drug release.
The aim of our work is to study the effect of for-
mulation variables (using soluble and insoluble fillers
and citric acid) on drug release and their relation to
specific surface area, bulk density, apparent density,
porosity and porosity parameters. Ibuprofen was used
as a model drug which has a pH-dependent solubility.
Pellets were prepared by the extrusion-spheronization
method.
2. Experimental procedure
2.1. Materials
In this work, ibuprofen (Shasun, batch IBU
0001097, particle size of 70.04 ± 3.8m, shelf-life
12/04) was used as a model drug with pH-dependent
solubility. Microcrystalline cellulose (Microcel PH
101, Sagran, Milan, Italy). Lactose monohydrate
(Granular® 200, Meggle, Wasserburg, Germany) and
tricalcium phosphate (Lusifar, Lisbon, Portugal) were
used as soluble and insoluble fillers, respectively, and
citric acid (Vaz Pereira, Portugal) as a pH adjuster.
Sodium hydroxide and potassium dihydrogenophos-
phate, analytical grade (Merck), were used in pH
7.2 ± 0.05 phosphate buffer preparation.
Ibuprofen solubility at pH 7.2± 0.05 and at a tem-
perature of 37±0.5 ◦C, was determined spectrophoto-
metrically at 264 nm (Shimadzu UV-1603, Shimadzu
Co., Kyoto, Japan). The apparent powder densities
were determined using a helium pycnometer (Accu-
Pyc 1330, Micromeritics, Norcross, USA).
Table 1
Physical characteristics of ibuprofen and excipients
Raw materials Specific
surface area
(m2 g−1)
Apparent
density at
24± 1◦C
(g cm−3)
Solubility
at 25 ◦C
(mg ml−1)
Ibuprofen 1.118± 0.001 6.5a
Monohydrate
lactose
0.24–0.25b 1.542 ± 0.002 215.98b
Tricalcium
phosphate
70–80b 2.985± 0.003 0.01c
Citric acid 1.57± 0.001 >1000b
Microcel PH 101 1.06–1.12b 1.580 ± 0.001 0.0c
a HPE (2000).
b Determination at pH 7.2 ± 0.05 ◦C and 37± 0.5 ◦C.
c Sousa et al. (2002b).
These properties are shown in Table 1, as well as
solubility of excipients and their specific surface area
values obtained from the literature (HPE, 2000).
2.2. Preparation of pellets
Pellets were prepared by the extrusion-spheroniza-
tion method. Four different formulations were con-
sidered: two ternary mixtures of ibuprofen (I), lactose
(L) or tricalcium phosphate (P) and microcel (M) in
the relative proportions 2:3:5 (ILM or IPM) and two
four-component mixtures of the same components
plus 5% citric acid (C) in the relative proportions
2:2.5:0.5:5 (CILM or CIPM). Demineralysed water,
65% in volume to weight of dry matter (v/w), was
used as the wetting liquid. The powders were mixed
for 5 min (Kenwood mixer, UK) before the water
was added. Masses were extruded in an extruder
with cylinders (Caleua Model 10, Dorset, England),
fitted with a die of 1 mm diameter (Caleva Process,
Ltd., Dorset, UK). The extrudate was spheronized in
a spheronizer (G.B. Caleva, Ltd., Dorset, UK) fitted
with a radial cut plate, 250 mm diameter at 1020 rpm
for 4 min. The pellets obtained were dried in a flu-
idized bed dryer (Glatt, Binzen, Germany), for 10 min
at 50 ◦C. Pellets were then submitted to sieve analysis
using a set of British Standard sieves following a
√
2
progression from 500 to 2000m of mesh diameter,
and a mechanical sieve shaker, during 10 min. Pellets
characterization, for each formulation, was performed
on the size range of 1000–1400m.
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2.3. Pellets characterization
2.3.1. Crushing strength
Strength testing was performed in 20 pellets of each
formulation with an available Erweka radial force ap-
paratus (Erweka GmbH, Heusenstamm, Germany).
2.3.2. Specific surface area
The specific surface area of pellets for all for-
mulations was determined using the adsorption
isotherm derived by the Brunauer, Emmet and Teller
(BET) method as described by Sousa et al. (2002a).
The analysis was performed by a certified labora-
tory (LabGran—Instituto Pedro Nunes, Coimbra,
Portugal), using qualified equipment (ASAP 2000,
Micromeritics). In general, one determination was
deemed sufficient but with one sample (ILM) three
were carried out for validation purposes.
2.3.3. Density and porosity
Bulk and apparent densities, porosity, togheter with
porosity parameters, such as the mean pore diameter,
total pore volume, pore size distributions and pores
shapes, were determined before, during (t = 15 min),
and after dissolution (t = 480 min) using a qualified
mercury porosimeter (Poresizer 9320, Micromeritics).
The analysis was also performed by the above men-
tioned laboratory and again three determinations were
made for the ILM sample. The method is based on
the intrusion of mercury under pressure into the sam-
ple pores and is quantified using the adapted Wash-
burn equation (Lowell and Shields, 1991; Mehta et al.,
2000),
D = −4γ cos θ
P
(1)
where D is the pore diameter, γ is the surface ten-
sion of mercury (485 dyn/cm), θ is the contact angle
(130 ◦) and P is the pressure (≈2–30,000 psia). From
the above equation, a relationship between pore diam-
eter and pore volume of a porous material can be ob-
tained by measuring the apparent volumes. The total
pore surface area (S) is given by
S =
∫ Vtot
0 P dV
γ| cos θ| (2)
where P is the pressure, V is the intruded volume of
mercury and Vtot is the total intruded volume of mer-
cury. The mean pore diameter (D′mean) is calculated
from
D′mean =
4Vtot
S
(3)
Pore shape is, in turn, inferred from the mercury
intrusion–extrusion hysteresis.
2.3.4. Scanning electron microscopy
SEM was performed using a JEOL JSM-5310 scan-
ning electron microscope (JEOL, Tokyo, Japan).
2.3.5. In vitro dissolution studies
Dissolution was conducted in a USP (Method 1,
rotating basket) apparatus, at a speed of 100 rpm, in
6 × 900 ml of dissolution media (phosphate buffer
at pH 7.2 ± 0.05), maintained at 37 ± 0.5 ◦C, using
an automated assembly which consisted of a Fujitsu
Ergo Proe PC, with UV-1601PC software, a peristaltic
pump (Watson Marlow 205S, UK), a UV spectropho-
tometer (Shimadzu UV-1603, Kyoto, Japan), cell posi-
tioner (Shimadzu CPS-Controller, Kyoto, Japan), and
water bath fitted with a variable-speed stirrer (Vankel
UK7000, Essex, UK) and a heater (Vankel VK750D,
Essex, England). The released ibuprofen absorbance
was recorded automatically at 264 nm every 5 min for
8 h. The test was carried out in triplicate and a total of
18 dissolution curves were obtained for each formula-
tion. Mean dissolution times (MDT) at different time
points were determined from mean profiles obtained
from these 18 curves, as described previously (Costa
et al., 2003). In the original reference, variances of
dissolution times are also included. Tests conducted
with pellets in which the active substance is absent
have shown no absorption in the wavelength consid-
ered. After 480 min of dissolution, pellets were dried
under vacuum at 50 ◦C and weighed to determine the
percentage of weight loss.
3. Results and discussion
3.1. Specific surface area, densities and porosity
The specific area, apparent density and solubility of
excipients are shown in Table 1. Tricalcium phosphate,
used as an insoluble filler, presents a significantly
higher value for the specific surface area than the other
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Table 2
Pellet physical properties
Properties ILM CILM IPM CIPM
Crushing strength (N) 6.66± 1.08 9.80 ± 1.57 3.53± 0.78 5.10 ± 1.08
Specific surface area (m2 g−1) 0.47± 0.01 0.33 15.77 10.76
Bulk density (g cm−3) 1.19± 0.01 1.32 1.19 1.26
Apparent density (g cm−3) 1.44± 0.01 1.51 1.70 1.61
Porosity (%) 17.78± 0.55 13.10 29.78 24.28
Total pore surface area (m2 g−1) 7.91± 0.37 7.72 25.97 20.45
Median pore diameter (m) 1.11± 0.02 0.54 0.10 0.10
Uncertainties are indicated for replicated determinations.
materials and is also characterized by the highest ap-
parent density of all powders used. These properties
are reflected, as expected (Sousa et al., 1996, 2002b),
in the physical characteristics of the pellets obtained
(Table 2). In fact, specific surface area and appar-
ent density of the IPM and CIPM pellets are higher
than of those with lactose, indicating that they offer
a larger contact surface with the surroundings. This
explains their higher porosity values, with a 5 to 10
times smaller median pore diameter and a smaller pel-
let crushing strength than those containing lactose.
This larger contact surface is also shown by the lower
bulk density values in the IPM and CIPM pellets.
The porosity and specific surface area characteris-
tics indicate that drug release and dissolution from the
phosphate pellets is generally faster than with other
insoluble excipients (Mehta et al., 2000; Sousa et al.,
2002a). This is observed in the first 15 min of dissolu-
tion where MDT values are very similar for the ILM
and IPM pellets (see Table 3). For the same time pe-
riod, both the CILM and CIPM formulations resulted
in higher MDT values, indicating a delay in dissolu-
tion. This is shown in Fig. 1, which represents the drug
percent dissolved for formulations IPM, CIPM and
Table 3
Pellet physical properties after dissolving for 15 min
Properties ILM CILM IPM CIPM
Bulk density (g cm−3) 0.87 1.03 1.12 1.07
Apparent density (g cm−3) 1.38 1.40 1.70 1.64
Porosity (%) 36.87 26.87 34.23 34.48
Total pore surface
area (m2 g−1)
11.45 12.4 27.97 24.18
Median pore diameter (m) 1.93 1.18 0.18 0.60
MDT (min) 5.96 7.58 5.92 6.86
The corresponding MDT values are also given.
CILM versus drug percent dissolved for ILM Fig. 1(a)
and the correspondent time derivatives plot Fig. 1(b).
These representations emphasize the effects on the be-
ginning of dissolution, which would not otherwise be
easily observed resorting to more common dissolution
representations (e.g., Fig. 2) (Costa et al., 2003). In
spite of a slower initial release, the formulation CIPM,
due to an intermediate increase in rate, is the first to
attain complete dissolution. Formulation CILM is, in
turn, characterized by a slower release and is the one
that takes longer to attain complete dissolution. The
similarity is also clear between formulations ILM and
IPM. Fig. 1(a) also clearly shows the initial zero order
release in the case of formulation CILM.
3.2. The effects of citric acid
Dissolution results are in agreement with what is
expected from previous work (Goskonda et al., 1994;
Healy and Corrigan, 1996; Nykänen et al., 1999;
Krogars et al., 2000), using 5% citric acid in CILM and
CIPM formulations. During dissolution testing, there
is the possibility of an acidic micro-environment ex-
isting inside and in the closer vicinity of the pellets, in
spite of the presence of the buffer in the bulk solution,
making ibuprofen dissolution difficult and promoting
a delay in its release, since ibuprofen is an acidic
drug (pKa 4.4) (AHFH, 2002). The modeling of the
role of citric acid can also be shown through its influ-
ence on porosity parameters. In fact, specific surface
area values for formulations containing citric acid are
lower than those for the correspondent formulations
in the absence of this excipient. Bulk density values
are higher, lessening the penetration of the dissolu-
tion medium in the pellet, and also favoring the above
mentioned acidic micro-environment. This, in turn,
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Fig. 1. Graphical representations of: (a) test formulations IPM, CIPM and CILM dissolved drug percentage as a function of that of
formulation ILM (reference); (b) test formulations dissolved drug percentage time derivative as a function of the corresponding values for
the reference (n = 18).
diminishes the rates of both drug release and dissolu-
tion. In addition, we can observe that the presence of
citric acid decreases the median pore diameter in lac-
tose pellets, contributing to the delay in drug release.
The values of these porosity parameters are related
to the high solubility of citric acid and its influence
during pellets processing and drying. When water is
being removed during the drying phase, the dissolved
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Fig. 2. Dissolution profiles of formulations ILM, CILM, IPM and CIPM (n = 18).
substances recrystallyse (Berggren and Alderborn,
2001; Sousa et al., 2002b) and inter-particle distance
decreases, thus lowering porosity and pore size. In
CIPM pellets, citric acid does not produce such a pro-
nounced effect as in CILM pellets, due mainly to the
insolubility of the filler. In this case, during dissolu-
tion, large areas of ibuprofen particles are surrounded
by tricalcium phosphate, and are thus not directly
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adjacent to the dissolving acid excipient. This dimin-
ishes the delaying influence of citric acid on solubility
and dissolution (Healy and Corrigan, 1996). More-
over, as we have seen above for the CILM formulation,
this delay is maintained until the end of dissolution,
while for CIPM a release compensation occurs.
In summary, ILM and IPM present similar MDT
values. Lactose is a soluble excipient, but displays a
lower specific surface area than the insoluble trical-
cium phosphate. For the latter, the large difference
between bulk and apparent densities associated with
a small median pore diameter suggests the existence
of air entrapment, causing a delay on the dissolution
medium penetration and, in consequence, in the drug
release. Addition of citric acid causes a delay in the
initial part of dissolution in both lactose and phos-
phate formulations, but the overall release is faster for
phosphate than lactose pellets. This difference may be
explained by the fact that in CIPM pellets, citric acid
dissolution “opens the way” to drug release, increas-
ing the contact surface with the solvent and facilitating
its ingress.
3.3. Variation of porosity parameters during
dissolution
All our formulations contain microcrystalline cel-
lulose and, as other authors have previously reported
(Santos et al., 2002; Tho et al., 2002), pellets do not
disintegrate during in vitro dissolution. They were re-
covered at dissolution times t = 15 min and t =
480 min, dried and submitted to mercury porosimeter
analysis (see Tables 3 and 4). Point t = 15 min was
chosen because it corresponds to the change point in
dissolution rate of CIPM pellets (see Fig. 1), and point
Table 4
Pellet physical properties after complete dissolution (480 min)
Properties ILM CILM IPM CIPM
Bulk density (g cm−3) 0.76 0.83 1.07 1.06
Apparent density (g cm−3) 1.31 1.32 1.77 1.74
Porosity (%) 42.04 37 39.59 39.27
Total pore surface area (m2 g−1) 13.28 15.23 33.62 29.47
Median pore diameter (m) 2.62 1.76 0.21 1.43
MDT (min) 60 93 64 46
Weight loss after dissolution
testing (%)
50.52 ± 0.54 50.21± 0.4 20.66± 0.49 25.67± 0.29
The corresponding MDT values and final weight losses are also presented.
t = 480 min is the last point in all dissolution curves.
As expected, porosity and median pore diameter are
found to increase with dissolution in all cases (see
Fig. 3). Samples collected at the first 15 min of disso-
lution show that initially there is a drastic increase in
these properties, especially for IPM and CIPM formu-
lations, indicating that diffusion through the pores is
probably the main mechanism ruling the drug release
(Vergote et al., 2001). However, a certain degree of
erosion in the inside of pores must also concomitantly
take place. The initial ratio between median pore di-
ameters in pellets containing lactose and pellets with
tricalcium phosphate is, grosso modo, maintained dur-
ing dissolution. The same does not apply for porosity
values, once formulations containing lactose attain full
dissolution of the active substance with a much higher
increase in porosity than formulations containing tri-
calcium phosphate. This is mainly due to the substan-
tial weight loss of ca. 50% in ILM and CILM pellets,
due to dissolution of excipients with the exception of
microcel (Table 4).
As discussed before, during dissolution pellets con-
taining citric acid perform very differently depending
on whether the filler is lactose or tricalcium phosphate.
Citric acid reduces lactose pellets median pore diam-
eter in comparison to those corresponding to ILM and
for the extracted samples collected along dissolution.
In contrast, this parameter is increased considerably
along dissolution, now comparing to the IPM formu-
lation. These findings may justify the different behav-
iors at later stages of dissolution of formulations CILM
and CIPM.
The drug release rates are dependent, thus, not only
on porosity values but also on total pore surface area
and median pore diameter. The CIPM formulation,
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Fig. 3. Relationship between MDT values for the various formulation and median pore diameters (solid line) and porosities (dotted line).
Lines were used for guiding the eye only.
which displays the fastest overall release, presents dur-
ing dissolution a high porosity, a high total pore sur-
face area values, and a median pore diameter of ca.
1m. The IPM formulation, on the other hand, has a
median pore diameter of ca. 0.2m. It also seems that
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Fig. 4. Mercury intrusion (i) and extrusion (e) curves for formulations ILM, CILM, IPM and CIPM, at the indicated time points.
high porosity and total pore surface area with small
median pore diameter (less than 1m) produces sim-
ilar dissolution results to those of low porosity and
low total pore surface area values in conjunction with
a high median pore diameter.
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3.3.1. Shape and pore size distribution
Fig. 4 shows the cumulative intrusion–extrusion
mercury volume plotted versus the mean pore di-
ameter of the four formulations considered before
(t = 0 min), during (15 min) and after dissolution
(480 min). Fig. 5 shows the incremental intrusion
volume and also the mean pore diameter of the same
formulations. From these figures we can see that all
formulations have pores with a large range of sizes
and with significant differences in the respective
frequency. Pellets containing lactose suffer drastic
changes during dissolution while those with trical-
cium phosphate only show modest variations (Fig. 5).
However, the CIPM structure presents a considerable
increment of frequency related to the higher values of
pore diameters (10–100m), which explains the rel-
ative high values of its median pore diameters during
and after dissolution.
All cumulative intrusion curves (Fig. 4) show
hysteresis connected to mercury pore entrapment
(Fujiwara et al., 1966; Orr, 1970; Lowell and Shields,
1991). This could be due to larger pore base diam-
eters in relation to pore entrance diameters. This
corresponds to a significant fraction of pores with an
“ink-bottle” shape as previously reported (Shively,
1991; Mehta et al., 2000; Byrne and Deasy, 2002).
In pellets containing lactose, the extruded mercury
volume is smaller than that in the tricalcium phos-
phate pellets, indicating that the pore base dimensions
of ILM and CILM pellets are higher, relatively to
the entrance parameter diameter, than those from
the CIPM and IPM pellets. Other supporting evi-
dence for this is the huge difference between specific
surface area determined by gas adsorption and to-
tal pore area determined by mercury penetration,
specially for ILM and CILM pellets (see Table 2).
With this last method, intrusion into the wide pore
inner body will not occur until sufficient pressure
is applied to force the mercury into the narrow en-
trance. It will, therefore, appear as if a large volume
was intruded into narrow pores, generating an ex-
cessively high calculated surface area (Lowell and
Shields, 1991).
The CILM pellets at t = 15 min and t = 480 min
have a high frequency of mean pore diameters in the
0.3–3m range (Fig. 5). However, this could imply
some pores with this entrance diameter range and a
wide inner body, rather than a large number of pores
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Fig. 6. SEM micro-photographs of ILM and CILM formulations. Magnifications: 35× and 350×.
Fig. 7. SEM micro-photographs of IPM and CIPM formulations. Magnifications: 35× and 350×.
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with these dimensions. This could emerge as an addi-
tional factor for the drug release delay observed with
this formulation.
3.4. SEM
Micro-photographs of the four considered pellets
formulations are shown in Figs. 6 and 7. One can see
that IPM and CIPM pellets have a smoother surface
than ILM and CILM pellets, due to their tiny pore
entrance diameters, which could be a valuable property
for subsequent technological treatment (e.g. coating
and packing).
4. Conclusions
Pellets with the soluble filler lactose and pellets con-
taining the insoluble filler tricalcium phosphate have
produced similar in vitro release profiles of the model
drug ibuprofen. On the other hand, when 5% of fillers
were replaced by citric acid, we have witnessed differ-
ent dissolution behaviors, i.e., in lactose pellets citric
acid induced a drug release delay, while in tricalcium
phosphate pellets a delay was noticed only during the
first 15 min, with this formulation being the first to
reach complete dissolution.
Porosity and porosity parameters, such as total pore
surface area, mean pore diameter, pores size distribu-
tion and pores shape, contribute to explain this find-
ings and, along with excipients physical properties as
solubility, density and specific surface area, can help
predicting drug release profiles of multi-unit dosage
forms.
Tricalcium phosphate containing pellets prove to be
smoother, due to their high porosity values and low
pore sizes, which is a useful property to consider for
subsequent technological treatment.
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